Nature Communications (Jul 2022)
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
- Anahita Fathi,
- Christine Dahlke,
- Verena Krähling,
- Alexandra Kupke,
- Nisreen M. A. Okba,
- Matthijs P. Raadsen,
- Jasmin Heidepriem,
- Marcel A. Müller,
- Grigori Paris,
- Susan Lassen,
- Michael Klüver,
- Asisa Volz,
- Till Koch,
- My L. Ly,
- Monika Friedrich,
- Robert Fux,
- Alina Tscherne,
- Georgia Kalodimou,
- Stefan Schmiedel,
- Victor M. Corman,
- Thomas Hesterkamp,
- Christian Drosten,
- Felix F. Loeffler,
- Bart L. Haagmans,
- Gerd Sutter,
- Stephan Becker,
- Marylyn M. Addo
Affiliations
- Anahita Fathi
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
- Christine Dahlke
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
- Verena Krähling
- Philipps University Marburg, Institute of Virology
- Alexandra Kupke
- Philipps University Marburg, Institute of Virology
- Nisreen M. A. Okba
- Erasmus Medical Center, Department of Viroscience
- Matthijs P. Raadsen
- Erasmus Medical Center, Department of Viroscience
- Jasmin Heidepriem
- Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems
- Marcel A. Müller
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology
- Grigori Paris
- Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems
- Susan Lassen
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
- Michael Klüver
- Philipps University Marburg, Institute of Virology
- Asisa Volz
- University of Veterinary Medicine Hanover, Institute of Virology
- Till Koch
- Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
- My L. Ly
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
- Monika Friedrich
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
- Robert Fux
- LMU University of Munich, Institute of Infectious Diseases and Zoonoses
- Alina Tscherne
- LMU University of Munich, Institute of Infectious Diseases and Zoonoses
- Georgia Kalodimou
- LMU University of Munich, Institute of Infectious Diseases and Zoonoses
- Stefan Schmiedel
- German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems
- Victor M. Corman
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology
- Thomas Hesterkamp
- German Center for Infection Research, Translational Project Management Office
- Christian Drosten
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology
- Felix F. Loeffler
- Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems
- Bart L. Haagmans
- Erasmus Medical Center, Department of Viroscience
- Gerd Sutter
- LMU University of Munich, Institute of Infectious Diseases and Zoonoses
- Stephan Becker
- Philipps University Marburg, Institute of Virology
- Marylyn M. Addo
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
- DOI
- https://doi.org/10.1038/s41467-022-31557-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
In a clinical trial, Fathi et al. show that a booster vaccination with a vector vaccine candidate against the highly pathogenic Middle East Respiratory Syndrome coronavirus is safe and strongly improves the immunity generated by primary immunization.
